Measures to enable immunocompromised and immunosuppressed patients to live with covid-19

That this House regrets the continued failure of Government to protect people who have moderate to severe immune compromise from covid-19 infection, by failing to make Evusheld available on the NHS when it was at its most effective against covid strains; notes with alarm the disbandment of the Enhanced Protection Programme, Covid-19 Antivirals and Therapeutics Taskforce, ONS Covid-19 Infection Survey and the closure of Covid Medicine Delivery Units since 31 March 2023; deeply regrets that patients have had to cancel routine medical appointments and surgery in fear of potentially lethal covid infection; further regrets that many patients are entering a fourth year of shielding or social distancing, losing out on employment and opportunities; applauds the campaigning efforts of Evusheld for the UK and Forgotten Lives UK, and the many patient groups calling for action; further notes with alarm that the spring booster vaccination programme has not been adequately promoted; also notes with alarm new NHS advice that, from 27 June 2023, immunocompromised patients will no longer be automatically contacted by the NHS about treatments after reporting a positive covid result; notes the engagement of the National Institute for Health and Care Excellence with patient advocacy groups to accelerate access to effective drugs and treatments; and calls on the Government to urgently establish a vulnerable patients task force to accelerate access to effective drugs and treatments for immunocompromised patients and to develop a strategy to enable people who have moderate to severe immune compromise from covid-19 infection, to live with covid.